



FluMist Quadrivalent
Influenza Vaccine Live, Intranasal

**START
HERE**

Educate Your Patients About FluMist Quadrivalent

FluMist Quadrivalent is the only nasal-spray flu vaccine for eligible individuals **2-49 years of age** that begins building mucosal immunity at the viral site of entry—the nose.¹⁻³

Select Safety Information

FluMist Quadrivalent is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FluMist Quadrivalent is for intranasal administration only.

Please see accompanying complete Product Information, including Patient Information.



FluMist® Quadrivalent is the only nasal-spray flu vaccine that helps protect against 4 influenza strains contained in the vaccine—2 A strains and 2 B strains¹

- It is needle-free¹
- It is administered in the nose¹
- There is no need to inhale during dosing¹
- Immunity occurs within 2 weeks like with the flu shot⁴
- FluMist Quadrivalent cannot guarantee 100% protection¹



Eligible children and adults 2-49 years of age can receive FluMist Quadrivalent¹

- Both children and adults receive the same dosage¹
 - As with any flu vaccine, a second dose may be necessary for children 2-8 years of age¹
- Persons with minor illnesses (i.e., congestion) can still receive the vaccine⁵



FluMist Quadrivalent is a live attenuated influenza vaccine (LAIV)^{1,6}

- The odds of reversion to wild-type influenza—the only way the vaccine virus can produce illness—are 1 in 100 quintillion replication cycles, equating to more than a millennium in time⁷⁻⁹
- Serious illnesses have not been reported among unvaccinated persons who have been inadvertently infected by vaccine viruses¹⁰

The most common side effects include¹:

- Runny or stuffy nose in recipients ages 2-49
- Sore throat in adults ages 18-49
- Fever >100°F in children ages 2-6

FluMist Quadrivalent is not made with thimerosal, mercury, or other preservatives¹

According to the Centers for Disease Control and Prevention (CDC)/ Advisory Committee on Immunization Practices:

- Eligible persons can receive FluMist Quadrivalent if they are in contact with others with lesser degrees of immunosuppression (e.g., people with diabetes or people with asthma)¹¹
 - Healthcare personnel in neonatal intensive care units or oncology clinics may receive LAIV¹¹
 - LAIV can be used for healthcare providers who work in any setting, except those who care for severely immunocompromised hospitalized persons who require care in a protective environment (e.g., bone marrow transplant unit)¹¹
- People should not receive FluMist Quadrivalent if they are in contact with others with severely weakened immune systems when they are being cared for in a protective environment (e.g., people with hematopoietic stem cell transplants)¹¹

Select Safety Information

FluMist Quadrivalent is contraindicated in persons who have had a severe allergic reaction to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist® (Influenza Vaccine Live, Intranasal). Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FluMist Quadrivalent administration.


FluMist Quadrivalent has not been studied in persons with severe asthma or active wheezing.



FluMist Quadrivalent
Influenza Vaccine Live, Intranasal

Nearly 13 million doses of FluMist Quadrivalent have been distributed in the 2013-2014 flu season¹²

- More than 64 million doses of trivalent FluMist® (Influenza Vaccine Live, Intranasal) have been distributed over the past 10 years¹²



Choose FluMist® Quadrivalent—a 4-strain vaccine that STARTS working where the flu starts infecting¹⁻³

- FluMist Quadrivalent is the only nasal-spray flu vaccine that helps protect against 4 influenza strains contained in the vaccine¹
- Eligible children and adults ages 2-49 can receive FluMist Quadrivalent¹
- FluMist Quadrivalent is a live attenuated influenza vaccine (LAIV)^{1,6}
- The most common side effects are runny or stuffy nose, sore throat, and fever over 100°F¹
- Nearly 13 million doses of FluMist Quadrivalent have been given in the 2013-2014 season¹²

Select Safety Information

If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FluMist Quadrivalent should be based on careful consideration of the potential benefits and risks. FluMist Quadrivalent has not been studied in immunocompromised persons. The safety of FluMist Quadrivalent in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established. FluMist Quadrivalent may not protect all individuals receiving the vaccine.

The most common solicited adverse reactions (occurring $\geq 10\%$ in vaccine recipients and at least 5% greater than in placebo) reported after FluMist were runny nose or nasal congestion in all persons 2-49 years, fever $>100^\circ\text{F}$ in children 2-6 years, and sore throat in adults 18-49 years. Among children 2-17 years who received FluMist Quadrivalent, 32% reported runny nose or nasal congestion and 7% reported fever $>100^\circ\text{F}$. Among adults 18-49 years who received FluMist Quadrivalent, 44% reported runny nose or nasal congestion and 19% reported sore throat.

Please see accompanying complete Product Information, including Patient Information.



Specialty Care Division of AstraZeneca

Gaithersburg, MD 20878 © 2014 MedImmune. All rights reserved.
29922A 1-877-FLUMIST (358-6478) www.FluMistQuadrivalent.com



FluMist® Quadrivalent
Influenza Vaccine Live, Intranasal

References:

1. FluMist Quadrivalent [package insert]. Gaithersburg, MD: MedImmune.
2. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. *J Infect Dis.* 2000;181(3):1133–1137.
3. Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. *Vaccine.* 2000;18(9-10):899–906.
4. Centers for Disease Control and Prevention. Live, intranasal influenza vaccine information statement 2013-2014. <http://www.cdc.gov/vaccines/hcp/vis/vis-statements/flulive.html>. Accessed February 25, 2014.
5. Centers for Disease Control and Prevention. Live attenuated influenza vaccine [LAIV] (the nasal spray flu vaccine). <http://www.cdc.gov/flu/about/qa/nasalspray.htm>. Accessed February 13, 2014.
6. Maassab H, Bryant ML. The development of live attenuated cold-adapted influenza virus vaccine for humans. *Rev Med Virol.* 1999;9(4):237–244.
7. Kamps BS, Hoffmann C, Preiser W, eds. *Influenza Report 2006*. Paris, France: Flying Publisher; 2006.
8. Smith DB, Inglis SC. The mutation rate and variability of eukaryotic viruses: an analytical review. *J Gen Virol.* 1987;68(pt 11):2729–2740.
9. Nobusawa E, Katsuhiko S. Comparison of the mutation rates of human influenza A and B viruses. *J Virol.* 2006;80(7):3675–3678.
10. Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. *Pediatr Infect Dis J.* 2006;25(7):590-595.
11. Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR). Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2013-2014. <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6207a1.htm>. Accessed April 17, 2013.
12. Data on File. MedImmune. Gaithersburg, MD.



Specialty Care Division of AstraZeneca

Gaithersburg, MD 20878 © 2014 MedImmune. All rights reserved.

29922A-247804 1-877-FLUMIST (358-6478) www.FluMistQuadrivalent.com